IO Biotech
IO Biotech is a clinical stage biotech company developing disruptive immune modulating anti-cancer therapies.
They develop peptide-based vaccines using T-win®, a new class of immune modulating therapies designed to engage and activate T-cells, that specifically target cells that express immune suppressive molecules such as the checkpoint molecule PD-L1 and the catabolic enzyme IDO.
On December 15, 2020, the U.S. Food and Drug Administration (FDA) granted IO Biotech breakthrough therapy designation for a combination of the potential therapies IO102 and IO103 with anti-PD-1 monoclonal antibodies for patients with unresectable or metastatic melanoma.
